Jupiter receives FDA clearance of IND application to initiate Phase 2 trial

Jupiter Neurosciences (JUNS) announced that the U.S. Food and Drug Administration, FDA, has cleared its Investigational New Drug, IND, application to initiate a Phase 2a clinical trial of JOTROL in patients with Parkinson’s disease. The FDA’s clearance marks a significant regulatory milestone for Jupiter, enabling the Company to begin enrollment in its exploratory Phase 2a trial designed to evaluate the safety and tolerability of JOTROL in patients with Parkinson’s, with secondary and exploratory endpoints to assess pharmacokinetics/pharmacodynamics of the drug.